Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Results of Operations and Financial Condition

Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Results of Operations and Financial Condition

Story continues below


Results of Operations and Financial

On May15, 2017, Aradigm Corporation (the Company) announced via
press release the Companys financial results for its first
quarter ended March31, 2017. A copy of the Companys press release
is attached hereto as Exhibit 99.1 and is incorporated herein by

The information in the report, including Exhibit 99.1 attached
hereto, shall not be deemed to be filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The
information contained herein and in the accompanying exhibit
shall not be incorporated by reference into any filing with the
U.S. Securities and Exchange Commission made by the Company,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release of Aradigm Corporation dated May15, 2017.

About Aradigm Corporation (NASDAQ:ARDM)

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Aradigm Corporation (NASDAQ:ARDM) Recent Trading Information

Aradigm Corporation (NASDAQ:ARDM) closed its last trading session down -0.109 at 0.834 with 106,139 shares trading hands.

An ad to help with our costs